
🏳️🌈Consultant Cardiologist -💔 failure and CIED at University Hospital Southampton. Fair weather diver. Irritant to @adair_alan. Father to #Worf
Joined April 2011
- Tweets1.3K
- Following374
- Followers760
- Likes2.3K
Paul Haydock retweeted
There’s a part of the NHS that almost nobody in the NHS has heard of. The CMO called it “critical, but increasingly fragile”.
While everyone talks about neighbourhoods and care closer to home, this is what closer to home already looks like. And it’s closing. 🧵
Mixed experience with @British_Airways today. MPL>LGW cancelled. Replacement flight offered for 02/09/26 MRS>LHR… helpful man on phone changed flight to NCE>LGW apparently confirmed but actually standby. V. Helpful ground staff got us on NCE>LCY but sadly bags haven’t followed😞
4
1,287
Paul Haydock retweeted
So slashing hospital beds, decade after decade whilst our population increases, can’t be fixed by pretending patients are in hospital?!
Who’d a thought it. 🤦🏻♂️😂
Now tell us how much we’ve spent across the whole system pretending to provide hospital care?
In case you missed it:
A study of more than 236,000 patients found no consistent evidence that NHS virtual wards reduce hospital admissions, length of stay or readmission rates.
eu1.hubs.ly/H0xLfzQ0
Paul Haydock retweeted
The Right Approach- For Whom?
Check out my latest on NEJM Voices: A cardiologist learns that end-of-life care is an iterative process.
And please sign up for FREE email alerts (link below) so you're always aware when a new piece drops!
voices.nejm.org/doi/full/10.…
Paul Haydock retweeted
1 New JAMA paper from the NHLBI HCM Registry reinforces the importance of CMR scar for arrhythmic risk prediction.
In nearly 2700 patients with HCM and ~7 years’ follow-up, LGE burden was one of the strongest predictors of SCD/ventricular arrhythmic events.
#WhyCMR #CardioTwitter
Paul Haydock retweeted
Some reflections on the challenges of oncology leadership in a system where support roles are reducing, many of us work below our skillset & ambition outpaces delivery capacity.
When do we stop pretending everything is possible?
We can't keep saying yes. lucygossage.com/we-cant-keep…
Amazing effort by Jasmine - another person living their best life thanks to the incredible congenital surgical team @UHSFT supported by @UkHeartbeat bbc.co.uk/news/articles/czx7…
2
146
Paul Haydock retweeted
In the news 📰
Great to see coverage in @TheSun of a paperclip-sized sensor - now recommended by @NICEComms to help patients monitor their heart condition from home 🏡
@drflett at @UHSFT led Southampton's involvement in the research that led to this 👇
thesun.co.uk/health/38127862…
UK ICSs should be perfectly positioned to prevent this but unless you integrate HF services and benchmark appropriately, similarly bad things happen in a system in which there is ‘no money for anything…’ You can’t ‘left shift’ without thinking about this.
I heard from an administrative colleague about a meeting that made his jaw drop.
He was summoned to an “emergency summit” to discuss his health system’s decline in heart failure admissions.
The cardiology department had been focused on reducing heart failure admissions and readmissions
The focus of the “summit” would make anyone with a consicence blush:
How do we increase our heart failure admissions?
The most benign view is that the system wanted to get a larger share of a shrinking pie of admissions in the community.
But the subtext of the meeting was unmistakeable: when patients win, hospitals lose.
In many ways, outpatient management of heart failure was “too effective.”
High margin heart failure admissions and ICU stays were shrinking in number.
And, yet, rather than declaring victory and the stunning success of the cardiology team, the hospital was in a panic.
Revenue was declining—and the hospital’s finances were suddenly in disarray.
They needed more admissions—and fast.
Said another way, they needed more sick people to need their services.
Traditional administrators would say the dynamic is an outgrowth of our broken fee-for-service health systems.
That incentives from value-based care do not make up for loss of volume.
But there’s something more nefarious in this short vignette: it’s the unquestioned institutional focus on finance over health.
“No margin, no mission,” some might glibly say.
But has the mission been fundamentally corrupted?
Is our mission:
Keeping our beds full?
Our margins high?
Our doors open?
Our teams employed at all costs?
Or is our mission to promote the health and well-being of the community?
We have clearly lost our way in important respects.
For if it was the latter, the emergency heart failure admissions meeting would not be an institutional crisis, but a celebration.
Celebration of community health.
Celebration that patients were able to spend more time at home than in the hospital.
Celebration that patients were healthier and so needed services less, not more.
But, yet, health service organizations too often measure themselves by traditional business metrics:
Volume.
Revenue.
Profit.
Which of course are the wrong metrics for (mostly not-for-profit) health systems and hospitals who are chartered to serve the public good.
It is the (hard) work of hospital administration to work proactively with payers to ensure that they are financially rewarded for doing the right thing.
Not to blame the system and perverse incentives.
forbes.com/sites/sachinjain/…
1
3
370
Look at this estimated prevalence in people >50yrs. UK not very different from Portugal - no wonder services can’t cope if we are benchmarking against cks.nice.org.uk/topics/heart…
New large population-based study provides updated estimation about the prevalence and phenotypic distribution of heart failure in Portugal
doi.org/10.1093/eurheartj/eh…
#heartfailure #cardiotwitter @ESC_Journals @escardio
6
3
203
Paul Haydock retweeted
I'm sure this won't be the least bit controversial 👀
The problem with hospitalization endpoints in #heartfailure trials
onlinelibrary.wiley.com/doi/…
@EJHFEiC @HFA_President @LTHTResearch @UoL_LICAMM
Paul Haydock retweeted
Earlier today one of the BBC's leading stories was about patient harm after heart surgery in Newcastle, the focus upon a single surgeon
This highlighted text caught my eye
Why? Because we've been here before sadly...
1/3
V. Helpful for anyone involved in acute cardiology practice - especially doctors in training / fellows @TheBJCA @BritishCardioSo
Sepsis-induced cardiomyopathy: @ESC_Journals
🥸 Nicely done: please read full article - very useful.
😱 Here is the summary
👇👇👇
212
Interesting data - important clinical question here. Reinforces the need to practice thoughtfully and consider the phenotype.
WITHDRAW-AF RCT
📌 In👫w/ presumed AF-induced #cardiomyopathy & normalized #LVEF after SR restoration
👉 withdrawal of #HF therapy is not assoc w/ LVEF ⬇️ again in 90% of👫in the following 6-m
#EPeeps #afib #HeartFailure #CardioTwitter #MedTwitter @DrMarthaGulati @JagSinghMD
2
283
Paul Haydock retweeted
Relationship Between Exercise-Induced Cardiac Troponin Elevations and Occult Coronary Atherosclerosis in Middle-Aged Athletes: @JACCJournals
🥸 Athletes and myocardial injury
😱 Take a look here at the TREAT study (n=1,011):
👇👇👇
Paul Haydock retweeted
Best of #BCS2025. Catching up with friends for some great sessions
Paul Haydock retweeted
Join Dr Kaushik Guha at @KnowYourPulse #HRU2025 in Portsmouth on 9th June. Dive into heart failure and AF, earn CPD points, and network with healthcare pros.
📍 Marriott Hotel, Portsmouth
Register now: loom.ly/YBiGLpI
Paul Haydock retweeted
Our Annual Conference is only 7 weeks away!
Book you place to attend this year's event from Monday 2 - Wednesday 4 June at @mcr_central and experience:
✅ Three keynote presentations from Professor Deborah Lawlor, Dr @Kit_Yates_Maths and Professor @Charis_Oxford
✅ Subspecialty sessions from our Affiliated Societies
✅ International sessions from @escardio, @ACCinTouch, @irishcardiacsoc and @CSI_Con
✅ Our ever-popular Education Zone
✅ Additional opportunity to attend our educational conference courses
✅ Abstract posters
✅ Networking opportunities
✅ Industry Sponsored Symposium
Find out more and book during the Early Bird window to save! > tinyurl.com/BCSConferenceEar…
Please note, our sponsors and exhibitors have provided sponsorship to the BCS conference to support the cost of the meeting. Our sponsors have had no influence over the meeting agenda or arrangements, except for the industry sponsored symposia presentations. Our sponsors include Abbott Medical, Amarin, Amicus, AstraZeneca, Bayer, Bracco UK Ltd, Bristol Myers Squibb, Canon, Daiichi Sankyo, Edwards Lifesciences, Medis, Medtronic, Merck Sharpe & Dohme, Novartis, Novartis Medical, Pfizer, Pharma Nord, Philips, Sanofi and Zoll.

































